Next-Generation Bioprinting (NGB) Platform: Leveraging the Capabilities for the Translation of Bioprinting Procedures to Clinic

Next-Generation Bioprinting (NGB) Platform: Leveraging the Capabilities for the Translation of Bioprinting Procedures to Clinic

 Moderator: Niloufar Khosravi, PhD

Speaker: Fabien Guillemot, PhD

📅 DATE: Wednesday, June 26, 2024

⏰ TIME: 6:45 – 7:00 pm PT

WHERE: Hall 4A, Seattle Convention Center, Seattle, WA

In this session, we will explore how Poietis Next-Generation Bioprinting (NGB) Platform can address the limitations of current tissue engineering methods and fulfill unmet clinical needs. Next-Generation Bioprinting (NGB) Platform is designed to combine the advantages of Laser-Assisted Bioprinting (LAB) technology—such as high resolution and enhanced cell viability— with other bioprinting technologies like bioextrusion. This integration enables the fabrication of complex multi-cellular 3D constructs. Featuring robotic automation and innovative fluidics devices, the NGB platform enables transition of the bioprinted products from the laboratory to the clinic. We will showcase this translation capacity through our first bioprinted tissue therapeutics including skin and cartilage, that are being developed using the NGB platform.

Fabien Guillemot, PhD

Co-founder, President, CSO, Poietis. Fabien is an entrepreneur with over two decades of experience in Regenerative Medicine, holding a PhD in Material Science and a habilitation in Health and Life Sciences. A former researcher at INSERM and invited scholar at Harvard, he is a recognized pioneer in bioprinting. Fabien has also enhanced his scientific expertise with entrepreneurial training from HEC Paris